In this issue:
Impact of ambient temperature on disability measurements
Neurofilament light chain in CSF and prediction of disease activity in CIS and RRMS
Lipid profile and adiposity in predicting clinical course after a first demyelinating event
IFN in the treatment of clinically isolated syndromes
Long-term outcomes after AHSCT for MS
Three-times-weekly dosing of GA in RRMS
Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a CIS
A randomised trial of abatacept for RRMS
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and IFN beta in RRMS
Fingolimod initiation in MS and cardiovascular autonomic effects
Please login below to download this issue (PDF)